Myers D E, Sicheneder A, Clementson D, Dvorak N, Venkatachalam T, Sev A R, Chandan-Langlie M, Uckun F M
Wayne Hughes Institute, St. Paul, MN, USA.
Leuk Lymphoma. 1998 Apr;29(3-4):329-38. doi: 10.3109/10428199809068569.
We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted the manufacturing of a highly purified clinical-grade B43-Genistein preparation. In clonogenic assays, B43-Genistein elicited selective and potent cytotoxicity against CD19 antigen positive human leukemia cells. To our knowledge, this work represents the first effort of producing a clinical-grade genistein immunoconjugate for treatment of B-lineage leukemia and lymphoma.
我们已将鼠源单克隆抗CD19抗体B43与酪氨酸激酶抑制剂染料木黄酮偶联，以构建一种针对CD19抗原阳性血液系统恶性肿瘤的有效免疫偶联物。B43抗体、染料木黄酮和B43-染料木黄酮免疫偶联物的放大生产及纯化，使得能够制备出高纯度的临床级B43-染料木黄酮制剂。在集落形成试验中，B43-染料木黄酮对CD19抗原阳性的人白血病细胞产生了选择性且强效的细胞毒性。据我们所知，这项工作代表了生产用于治疗B系白血病和淋巴瘤的临床级染料木黄酮免疫偶联物的首次尝试。
